Department of Endocrinology
Obesity
-
Disease Introduction
-
Equipment Advantages
-
Treatment Cases
Disease Introduction
Disease Introduction
For overweight or obese patients, we assess systemic metabolic status through comprehensive evaluation and diagnosis, including obesity etiology, severity assessment, metabolic indicators, and complication risks, to tailor a personalized weight loss plan for each patient. When necessary, medical weight loss medications such as Semaglutide and Tirzepatide are administered. Injection guidance and disinfection protocols are provided.
Equipment Advantages
Equipment Advantages
-
1
Body Composition Analyzer
Clinical Cases
-
48 Units of Insulin Cannot Control Blood Sugar? A Fellow Patient Saw Results in Two Days with a New Drug, Becoming the Key to Treatment
-
Patient Profile
A 61-year-old male
-
Chief Complaints
Diagnosed with obese type 2 diabetes mellitus, requiring high doses of insulin with poor glycemic control; postprandial blood glucose levels range from 10 to 15 mmol/L.
-
Technical Highlights
Treatment with GLP-1 receptor agonists was initiated. Compared to conventional therapy, GLP-1 receptor agonists not only rapidly lower blood glucose in patients with obese type 2 diabetes but also promote weight loss, improve metabolism, and reduce insulin requirements.
-
Therapeutic Outcomes
After two days of GLP-1 receptor agonist therapy, blood glucose levels decreased significantly. At discharge, the insulin dose was reduced to 16 units, and fasting blood glucose was controlled within the range of 5 to 7 mmol/L.
-
